Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2011 Financial Results and Highlights
Date:5/5/2011

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its program highlights and financial results for the first quarter ended March 31, 2011.

"The ANA598 Phase IIb study currently underway will expand the profile of ANA598 in important ways," said Steve Worland, Ph.D., President and CEO of Anadys.  "We expect to increase the ANA598 safety database by approximately 200 patients, with dosing through 24 weeks completed by year-end, and to characterize ANA598's activity in combination with pegylated interferon and ribavirin in treatment-experienced patients.  The acquisition of these data should significantly enhance ANA598's readiness for Phase III activities."

Development Program Highlights

  • ANA598 Phase IIb Study.  During the first quarter, Anadys commenced dosing HCV patients in an ongoing Phase IIb study in which ANA598 is being tested in combination with interferon and ribavirin in both treatment-naive patients and patients who failed a prior course of therapy with interferon and ribavirin.  Approximately 275 patients are expected to be enrolled in the study.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients complete treatment, known as SVR24.  The Company expects to receive antiviral response data through 12 weeks for all patients, including the 8 week timepoint used for response-guided therapy in treatment-naive patients, in the third quarter of 2011.  Antiviral response data through 24 weeks are expected in the fourth quarter of 2011.  
  • ANA773 Phase IIa Study.  The Company is preparing to commence during the second quarter a 28-day study of ANA773 in combination with riba
    '/>"/>

  • SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
    3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
    4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
    5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
    6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
    7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
    9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
    10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
    11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/30/2015)... WOODBRIDGE, ON , April 30, 2015 /PRNewswire/ ... a specialty pharmaceutical company with a focus on ... health, announced its operational highlights and financial results ...  All dollar amounts referenced herein are in Canadian ... in 2014 have been significant, with the right ...
    (Date:4/30/2015)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider ... today announced results for its first quarter ended March ... first quarter of 2015 was $116.2 million, up $14.5 ... and down $5.3 million or 4.4% from the fourth ... income as reported in accordance with U.S. generally accepted ...
    (Date:4/30/2015)... Calif. , April 30, 2015  IRIDEX Corporation ... release its first quarter 2015 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, May ... quarter and other business developments. Interested parties ...
    Breaking Medicine Technology:Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27IRIDEX Announces First Quarter 2015 Conference Call and Release Date 2
    ... ProStrakan Group plc (LSE: PSK) today announced the ... the first rapidly-disintegrating tablet placed under the tongue for ... (F.D.A.) approved ABSTRAL, an opioid analgesic, in January 2011 ... patients, 18 years of age or older, ...
    ... Daiichi Sankyo, Inc. (DSI) announced today that John P. ... Effective today, Mr. Gargiulo succeeds Joseph P. Pieroni who is ... the past 14 years. "John,s experiences within ... him well for his new role and responsibility," said Joseph ...
    Cached Medicine Technology:ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 2ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 3ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 4ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 5ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 6ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S. 7John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc. 2
    (Date:5/3/2015)... “ BolehVPN ” was featured on NewsWatch as part ... coolest technology products available to consumers. Scott Steinberg, a technology ... shared with viewers how to protect their private information. , ... computers and even more so online. It helps everyone stay ... the world. In terms of work, the internet makes things ...
    (Date:5/3/2015)... 03, 2015 It is not too late to ... Walk in Memory of Lissa Anne Been in Arnold, Missouri ... great family-friendly event to honor her loving memory. It has benefited ... , Just having turned 37, Lissa suffered a brain aneurysm ... August 24, 2012. This event is designed to serve as a ...
    (Date:5/2/2015)... Vancouver fencing company, QS Fencing, has recently announced that ... clients related to their questions on railings and gates. Many ... decks and patios. While that seems like an easy task, ... person rolls up their sleeve to start working. One of ... a gate that matches it. , Instead of spending hours ...
    (Date:5/2/2015)... Delray Beach, FL (PRWEB) May 02, 2015 ... newspaper has selected The Delray Recovery Center as one ... Recovery Center is known in the addiction treatment field ... encourages staff members to innovate and to continue their ... promoting a positive workplace environment, never forgetting their purpose ...
    (Date:5/2/2015)... Southlake, TX (PRWEB) May 02, 2015 ... of skin laxity issues of the face, neck ... a new concept with real potential for the ... published by the ThermiHealth Clinical Advisory Council, ThermiGyn’s ... MD, FACOG, FACS, ACGE, concluded that ThermiGyn’s temperature ...
    Breaking Medicine News(10 mins):Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
    ... do not get training posts through the flawed Medical ... the government// is stalling on a new contract for ... figures show that 34,250 doctors are chasing 18,500 specialist ... far given no commitment that trainee doctors will be ...
    ... promising anti-inflammatory drug failed to improve symptoms of moderate ... a large, multi-center trial. ,The results ... published in the first issue of the May American ... the American Thoracic Society. ,According to an ...
    ... a heart attack or severe chest pain today are much less ... even a few years ago, according to a new international study. ... a significant drop in the rate of heart failure and death ... ,The study finds that the change occurred at the same time ...
    ... war veterans who have come back after combat in the ... chemicals and other harmful substances, there is a decreased volume ... and memory. ,Roberta White, chair of the department ... Health, revealed, at the American Academy of Neurology's 59th Annual ...
    ... alert following a malaria epidemic that has claimed at ... ,"Doctors and paramedics have been put on alert ... out to vulnerable areas to check the spread of ... ,Eight of Assam's 29 districts have been ...
    ... immediately spot the victims of a bite from the Brazilian ... and an increase in blood pressure, they also sport an ... quest for more Viagras. Scientists say they have figured out ... boost. , “The erection is a side effect ...
    Cached Medicine News:Health News:Junior Doctors Facing More Misery Because of Contract Deadlock: BMA 2Health News:Anti-inflammatory Drug Fails to Improve COPD Symptoms 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 3Health News:Good News for Sufferers of Heart Attack, Chest Pain 4Health News:Gulf War Veterans Exhibit Memory Impairment 2Health News:Malaria Claims 25 Lives in Assam 2Health News:Brazil Spider Offers Hope for Those Suffering from Erectile Dysfunction 2
    The TS100-F trinocular model comes with a photo port that accepts Nikon's FX-III series photomicrographic systems, CCTV camera, or digital camera....
    ... A standard laboratory microscope whose ... imagery combine to make it ... E400 is designed to fit ... the user to fit the ...
    ... incorporate the slight change in the difficulty ... letters derived from the best corrected visual ... ETDRS study. The original charts difficulty scores ... eyes. In addition to the revised arrangement ...
    Created to simplify stereopsis screening in children. Based on principles of random dots. No glasses are necessary for this stereo test, and the child's eye movement can be easily observed....
    Medicine Products: